Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 3/20 | 0.36 |
| ▸ | GABRD | O14764 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21988047 | 1.00 | RAB9A (0.37) | RAB9AKDM4ESMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL19304135 | 0.81 | AGBL2 (0.39) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12184911 | 0.81 | NOS3 (0.34) | RAB9ASMN1; SMN2HSD17B10GABRPGABRD | |
| SCHEMBL17512545 | 0.78 | TKT (0.30) | — | |
| SCHEMBL14658584 | 0.76 | TRPV1 (0.34) | — | |
| SCHEMBL22166113 | 0.75 | AGBL2 (0.37) | RAB9AKDM4ESMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL14659818 | 0.73 | DPP4 (0.33) | — | |
| SCHEMBL13952474 | 0.72 | TDP1 (0.38) | RAB9AKDM4ESMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL11240217 | 0.72 | CYP3A4 (0.41) | RAB9AKDM4ESMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL22049710 | 0.71 | TLR8 (0.45) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2023-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, IRF3, CGAS | RAB9A 928/4885KDM4E 4043/4885SMN1; SMN2 2822/4885 |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | RAB9A 876/4885KDM4E 3761/4885SMN1; SMN2 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.